Rebecca Spalding

Rebecca covers the drug industry for Bloomberg by following the money and the players behind one of the world's most lucrative sectors. She reports on companies at every stage, from private, venture-backed start-ups through $100 billion behemoths working across cutting-edge areas of science.

Rebecca also focusses on the capital markets and has covered some of the industry’s largest mergers, IPOs, and record-setting private financings. She has interviewed dozens of public company CEOs, investors, and venture capitalists changing the face of medicine.

Among other topics, she has written about a drug with a $2 million price tag, a Harvard professor who made $400 million in an biotechnology IPO, Blackstone's foray into drug development, and how Cambridge, Massachusetts came to be a magnet for the industry.

Before that, Rebecca helped cover the Puerto Rico debt crisis and unprecedented bankruptcy, made all the more tragic by Hurricane Maria. Her work has been cited at a congressional hearing, featured on Bloomberg radio and television, and through Bloomberg’s wire service has appeared in the Washington Post, Sydney Morning Herald, Seattle Times, Denver Post, and other publications.